MED1 and neoplasm: These fusions contribute to tumor progression by instigating oligomeric structures and nuclear condensates that concentrate transcription factors and co-activators, including bromodomain-containing protein 4 (BRD4), mediator of RNA polymerase II transcription subunit 1 (MED1), and TEAD, while concurrently excluding transcriptional repressors like the polycomb repressive complex 2 (PRC2) complex.